关注结核病共患病已成为公共卫生的需要

doi:10.19983/j.issn.2096-8493.20220107

摘要/Abstract

中图分类号:

卢水华. 关注结核病共患病已成为公共卫生的需要[J]. 结核与肺部疾病杂志, 2022, 3(4): 255-260. doi: 10.19983/j.issn.2096-8493.20220107

参考文献 35

[1]	Bates M, O’Grady J, Maeurer M, et al. Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis, 2013, 13(1):36-42. doi: 10.1016/S1473-3099(12)70245-1. doi: 10.1016/S1473-3099(12)70245-1 URL
[2]	Swindells S, Ramchandawi R, Gupta A, et al. One Moth of Rifapentine plus Isoniazid to prevent HIV-Related Tuberculosis. N Engl J Med, 2019, 380(11): 1001-1011. doi: 10.1056/NEJMoa1806808. doi: 10.1056/NEJMoa1806808 URL
[3]	Nemes E, Geldenhuys H, Rozot V, et al. tuberculosis Infection with H4:IC 31 Vaccine or BCG Revaccination. N Engl J Med, 2018, 379(2):138-149. doi: 10.1056/NEJMoa1714021. doi: 10.1056/NEJMoa1714021 URL
[4]	Ottenhoff THM. A Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N Engl J Med, 2020, 382(16):1576-1577. doi: 10.1056/NEJMc2001364. doi: 10.1056/NEJMc2001364 URL
[5]	Schrager LK, Vekemens J, Drager N, et al. The status of tuberculosis vaccine development. Lancet Infect Dis, 2020, 20(3)e28-e37.doi: 10.1016/S1473-3099(19)30625-5. doi: 10.1016/S1473-3099(19)30625-5
[6]	Zhu B, Dockrell HM, Ottenhoff THM, et al. Tuberculosis vaccines: Opportunities and challenges. Respirology, 2018, 23(4):359-368. doi: 10.1111/resp.13245. doi: 10.1111/resp.13245 URL
[7]	World Health Organization. Global tuberculosis report 2019. Geneva:World Health Organization,2019.
[8]	Elhadi M, Khaled A, Msherghi A. Infectious diseases as a cause of death among cancer patients: a trend analysis and population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results database. Infect Agent Cancer, 2021, 16(1):72. doi: 10.1186/s13027-021-00413-z. doi: 10.1186/s13027-021-00413-z URL
[9]	Lin CH, Lin CJ, Kuo YW, et al. Tuberculosis mortality: patient characteristics and causes. BMC Infect Dis, 2014, 14:5. doi: 10.1186/1471-2334-14-5. doi: 10.1186/1471-2334-14-5 URL
[10]	Puchner KP, Rodriguez-Fernandez R, Oliver M, et al. Non-communicable diseases and tuberculosis: Anticipating the impending global storm. Glob Public Health, 2019, 14(9):1372-1381. doi: 10.1080/17441692.2019.1580760. doi: 10.1080/17441692.2019.1580760 URL
[11]	Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis. Lancet Glob Health, 2019, 7(4):e448-e460. doi: 10.1016/S2214-109X(18)30487-X. doi: 10.1016/S2214-109X(18)30487-X
[12]	Shu CC, Liao KM, Chen YC, et al. The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse. Sci Rep, 2019, 9(1):11901. doi: 10.1038/s41598-019-48395-8. doi: 10.1038/s41598-019-48395-8 URL
[13]	Dong YH, Chang CH, Wu FL, et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials. Chest, 2014, 145(6):1286-1297. doi: 10.1378/chest.13-2137. doi: 10.1378/chest.13-2137 URL
[14]	Hu HY, Wu CY, Huang N, et al. Increased risk of tuberculosis in patients with end-stage renal disease: a population-based cohort study in Taiwan, a country of high incidence of end-stage renal disease. Epidemiol Infect, 2014, 142(1):191-199. doi: 10.1017/S0950268813000551. doi: 10.1017/S0950268813000551 pmid: 23510593
[15]	Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis, 2009, 48(12):1657-1665. doi: 10.1086/599035. doi: 10.1086/599035 pmid: 19445585
[16]	Lee HJ, Lee DG, Choi SM, et al. The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general population. PLoS One, 2017, 12(3):e0173250. doi: 10.1371/journal.pone.0173250. doi: 10.1371/journal.pone.0173250
[17]	Kedia S, Mouli VP, Kamat N, et al. Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis. Am J Gastroenterol, 2020, 115(3):340-349. doi: 10.14309/ajg.0000000000000527. doi: 10.14309/ajg.0000000000000527 URL
[18]	Sartori NS, de Andrade NPB, da Silva Chakr RM. Incidence of tuberculosis in patients receiving anti-TNF therapy for rheumatic diseases: a systematic review. Clin Rheumatol, 2020, 39(5):1439-1447. doi: 10.1007/s10067-019-04866-x. doi: 10.1007/s10067-019-04866-x URL
[19]	Hosseini M, Shakerimoghaddam A, Ghazalibina M, et al. Aspergillus coinfection among patients with pulmonary tuberculosis in Asia and Africa countries; A systematic review and meta-analysis of cross-sectional studies. Microb Pathog, 2020, 141:104018. doi: 10.1016/j.micpath.2020.104018. doi: 10.1016/j.micpath.2020.104018 URL
[20]	Wong RJ, Hubbard A, Bagley L, et al. Estimating Prevalence of Hepatitis B Virus Coinfection Among Adults With Tuberculosis: A Systematic Review With Meta-analysis. J Clin Gastroenterol, 2022, 56(7):601-617. doi: 10.1097/MCG.0000000000001533. doi: 10.1097/MCG.0000000000001533 URL
[21]	Behzadifar M, Heydarvand S, Behzadifar M, et al. Prevalence of Hepatitis C Virus in Tuberculosis Patients: A Systematic Review and Meta-Analysis. Ethiop J Health Sci, 2019, 29(1):945-956. doi: 10.4314/ejhs.v29i1.17. doi: 10.4314/ejhs.v29i1.17 pmid: 30700963
[22]	姚琳, 顾斌斌, 王霞芳, 等. 苏州地区2011年—2017年间9528例肺结核患者合并症的原因分析及其分布趋势. 抗感染药学, 2019, 16(2):258-261. doi: 10.13493/j.issn.1672-7878.2019.02-025. doi: 10.13493/j.issn.1672-7878.2019.02-025
[23]	邓岚兰, 杨新婷, 贾俊楠, 等. 2012—2016年北京市胸科医院肺结核合并症患者的回顾性分析. 疾病监测, 2018, 33(4):320-323.
[24]	Puchner KP, Rodriguez-Fernandez R, Oliver M, et al. Non-communicable diseases and tuberculosis: Anticipating the impending global storm. Glob Public Health, 2019, 14(9):1372-1381. doi: 10.1080/17441692.2019.1580760. doi: 10.1080/17441692.2019.1580760 URL
[25]	World Health Organization.World Health Statistics 2019.Geneva:World Health Organization, 2019.
[26]	The World Bank New World Bank country classifications by income level:2020-2021:[EB/OL].[2022-06-11]. https://blogs.worldbank.org/opendata/new-world-bank-country-classifications-income-level-2020-2021.
[27]	Sbrana E, Grise J, Stout C, et al. Co-morbidities associated with tuberculosis in an autopsy case series. Tuberculosis (Edinb), 2011, 91 Suppl 1:S38-42. doi: 10.1016/j.tube.2011.10.008. doi: 10.1016/j.tube.2011.10.008
[28]	Drug Interactions Checker[DB/OL].[2022-06-12]. https://www.drugs.com/drug_interactions.html.
[29]	Tao NN, Li YF, Song WM, et al. Risk factors for drug-resis-tant tuberculosis, the association between comorbidity status and drug-resistant patterns: a retrospective study of previously treated pulmonary tuberculosis in Shandong, China,during 2004—2019. BMJ Open, 2021, 11(6):e044349. doi: 10.1136/bmjopen-2020-044349. doi: 10.1136/bmjopen-2020-044349
[30]	何燕超, 揭志军. 综合医院活动性肺结核的早期筛查的进展与策略. 结核与肺部疾病杂志, 2022, 4(4):334-337. doi: 10.19983/j.issn.2096-8493.20220078. doi: 10.19983/j.issn.2096-8493.20220078
[31]	周伊南, 朱惠莉. 慢性阻塞性肺疾病合并肺结核的研究进展. 结核与肺部疾病杂志, 2022, 4(4):338-342. doi: 10.19983/j.issn.2096-8493.20220013. doi: 10.19983/j.issn.2096-8493.20220013
[32]	钱晓文, 翟晓文. 造血干细胞移植与结核病. 结核与肺部疾病杂志, 2022, 4(4):315-319. doi: 10.19983/j.issn.2096-8493.20220092. doi: 10.19983/j.issn.2096-8493.20220092
[33]	张晓林, 李锋. 肺结核致呼吸衰竭研究进展. 结核与肺部疾病杂志, 2022, 4(4):320-324. doi: 10.19983/j.issn.2096-8493.20220014. doi: 10.19983/j.issn.2096-8493.20220014
[34]	郦源, 郭茹茹, 吕良敬. 结缔组织病合并结核病的研究进展. 结核与肺部疾病杂志, 2022, 4(4):309-314. doi: 10.19983/j.issn.2096-8493.20220011. doi: 10.19983/j.issn.2096-8493.20220011
[35]	刘玉坤, 郭智. 慢性髓系白血病与结核病. 结核与肺部疾病杂志, 2022, 4(4):325-327. doi: 10.19983/j.issn.2096-8493.20220108. doi: 10.19983/j.issn.2096-8493.20220108

关注结核病共患病已成为公共卫生的需要

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 35

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	古力米娜·阿布力米提, 麦维兰江·阿不力米提, 地尔木拉提·吐逊, 刘振江, 何懿, 苏伟, 欧喜超. 2021年喀什地区肺结核患者利福平耐药影响因素分析[J]. 结核与肺部疾病杂志, 2022, 3(4): 269-273.
[2]	杨震, 雷囡, 赵飞, 何艳萍, 林娜, 张治国. 北京市昌平区高等院校新生结核分枝杆菌潜伏感染状况调查及潜伏感染者预防性治疗效果分析[J]. 结核与肺部疾病杂志, 2022, 3(4): 274-280.
[3]	董昭良, 姚黎明, 李领娣, 王连波, 姚晓伟, 李卓, 刘丰胜, 贾晨光. 保守方法治疗轻型脊柱结核的临床疗效[J]. 结核与肺部疾病杂志, 2022, 3(4): 281-286.
[4]	李义帅, 秦学博, 李香兰, 魏兰, 段小亮, 张磊, 陈亮, 李建行. 电视辅助胸腔镜手术与开胸手术治疗难治性空洞性肺结核的效果分析[J]. 结核与肺部疾病杂志, 2022, 3(4): 292-295.
[5]	李军霞, 孟艺哲, 张亚楠, 陈颜强, 赵青. 12例结核性神经根脊髓炎的临床特征及磁共振成像特点分析[J]. 结核与肺部疾病杂志, 2022, 3(4): 296-299.
[6]	胡娟, 周燕, 杨澄清. 支气管结核患者焦虑、抑郁心理状况与行电子支气管镜治疗依从性的相关性分析[J]. 结核与肺部疾病杂志, 2022, 3(4): 305-308.
[7]	郦源, 郭茹茹, 吕良敬. 结缔组织病合并结核病的研究进展[J]. 结核与肺部疾病杂志, 2022, 3(4): 309-314.
[8]	钱晓文, 翟晓文. 造血干细胞移植与结核病[J]. 结核与肺部疾病杂志, 2022, 3(4): 315-319.
[9]	张晓林, 李锋. 肺结核致呼吸衰竭研究进展[J]. 结核与肺部疾病杂志, 2022, 3(4): 320-324.
[10]	刘玉坤, 郭智. 慢性髓系白血病与结核病共病研究进展[J]. 结核与肺部疾病杂志, 2022, 3(4): 325-327.
[11]	何燕超, 揭志军. 综合医院活动性肺结核的早期筛查策略[J]. 结核与肺部疾病杂志, 2022, 3(4): 334-337.
[12]	周伊南, 朱惠莉. 慢性阻塞性肺疾病合并肺结核的研究进展[J]. 结核与肺部疾病杂志, 2022, 3(4): 338-342.
[13]	龚道敏, 朱凌, 田甜, 钟浈. 肺癌合并肺结核患者预感性悲伤影响因素分析[J]. 结核与肺部疾病杂志, 2022, 3(3): 193-197.
[14]	徐翠玲, 蒋钰辉, 徐芳. 超前镇痛护理干预对肺结核胸部术后镇痛的效果分析[J]. 结核与肺部疾病杂志, 2022, 3(3): 198-202.
[15]	张彦坤, 关艳, 韩朝, 章志华. 18例结核性后葡萄膜炎患者临床特征分析[J]. 结核与肺部疾病杂志, 2022, 3(3): 216-221.